← back to ranking

BDX · Becton, Dickinson and Company

Medical - Instruments & Supplies · mkt cap $52.3B · calls: Q2 FY2026 vs Q1 FY2026
58.0 conviction · conf-adj 57

conf 5/10 partial

enthusiasm:21.0 · trend:8 · quantifies:5 · impact:0 · under_radar:5 · credibility:12 · business_impact:8 · disruption:0 · commitment:-4 · confirmation:3

Enthusiasm latest 7 / prev 6 (rising)

BDX's AI thesis is centered on "AI-enabled Pyxis," "BD Incada," "AI-driven advanced patient monitoring," and pharmacy automation. The credibility improved in Q2 FY2026 because management moved from broad trend language to product-level claims and conversion metrics, including "75% of our wins are competitive conversions." Quantification exists, but it mostly measures AI-adjacent platforms and products rather than isolated AI contribution.

GROUNDED NEXT-FY IMPACT vs CONSENSUS

Grounded on actual base — revenue $21.8B · net income $1.7B · net margin 7.7% · diluted EPS 5.83

These are next-fiscal-year annual uplift estimates, not next-quarter numbers.

Aggregate next-FY est. rev uplift: 0.75% · next-FY EPS uplift: 0.74% · vs analysts: inline · priced in: medium (model's call-read: high; verdict above is the hard-data one used for ranking) · confidence: 5/10

ClaimFigureArithmeticNext-FY Rev %Next-FY EPS %
Connected Care AI-driven segment scale
other		nearly $5 billion~$4.9-5.0B AI-touched Connected Care (AI-driven APM + connected medication management) / $21,839M rev = ~22.6%. This is the DISCLOSED BASE the growth claims attach to, not an incremental next-FY AI uplift, so no rev/eps % is assigned. Anchored figure (disclosed-base rule) → soft=false.
Pyxis Pro 85% of initial orders are competitive conversions
engagement · soft		85% of initial ordersShare-gain signal. No Pyxis Pro / MMS automation revenue base disclosed in the inputs, so the conversion rate cannot be turned into incremental $ — directionally positive but unsizeable.
Pharmacy automation double-digit growth (LoRa)
revenue · soft		double-digitVague qualifier, superseded by the quantified 10% below. Pharmacy automation revenue base undisclosed (sits in MMS, distinct from the Connected Care base) → cannot size.
Pharmacy automation grew 10% in the quarter
revenue · soft		10% in the quarterGrowth RATE on an undisclosed base — pharmacy automation revenue (MMS sub-line, not the Connected Care figure) is not given in any claim, so 10% × ? cannot be evaluated. CapEx-heavy hardware+robotics line.
Pyxis Pro priced at a premium to base Pyxis
engagement · soft		premium (no number)No quantified premium and no Pyxis Pro unit volume/ASP base → unanchored. Mix-up is real but unsizeable on the inputs.
Pyxis Pro 75% of H1 wins are competitive conversions
engagement · soft		75% of winsSame share-gain signal as the 85% figure, restated for H1. No win-volume or revenue base disclosed → unsizeable.
APM grew 12%; Connected Care grew 3.3% (Q2)
revenue		APM +12% / Connected Care +3.3%Connected Care is the AI-driven segment with a DISCLOSED base (~$4.9-5.0B). Using the disclosed segment growth as the AI-attributable upper bound: ~$4.95B × 3.3% ≈ $163M incremental annual rev; $163M / $21,839M ≈ 0.75% rev uplift. Flow at corporate ADJUSTED net margin (3,245.6/21,839 = 14.86%, consistent with the adjusted NI denominator): $163M × 14.86% ≈ $24M; $24M / $3,245.6M adj NI ≈ 0.74% EPS uplift. APM +12% is the leading sub-driver but its standalone base is undisclosed, so the whole disclosed segment's organic growth is sized as the upper bound.0.750.74

Assumptions: Earnings basis = consensus ADJUSTED, not GAAP: GAAP NI $1,678M is depressed (consensus FY25 adj NI ≈ $3,245.6M, adj EPS ≈ $11.30); sizing EPS% off GAAP inflates the result, so adj NI is used. Revenue % uses disclosed current base $21,839M. Incremental margin = corporate ADJUSTED net margin 14.86% (kept at corporate average — no disclosure justifies a higher software rate). Critically, the flow-through margin is matched to the adjusted NI denominator, so rev% and EPS% are near-equal — using GAAP reported margin (7.68%) against an adjusted denominator, as one analyst did, understates the EPS lift. Tax 21% not invoked (no cost-saving claims). Phasing: Q2 segment growth rate treated as run-rate annual contribution, not compounded. Segment mapping: 'AI-driven' = ~$4.9-5.0B Connected Care; Pyxis/pharmacy automation sit in MMS with no disclosed base. Not all of Connected Care's 3.3% growth is AI-causal, so 0.75% is a generous upper bound.

Top line: Only one claim is sizeable on the disclosed inputs: the AI-driven Connected Care segment (~$4.9-5.0B, ~22.6% of revenue) grew 3.3% in Q2, led by AI-driven APM +12%. Taken at face value that is ~$163M incremental annual revenue = +0.75% on the $21,839M base. Everything else — Pyxis Pro's 85%/75% competitive-conversion wins, double-digit/10% pharmacy automation growth, and the price premium — is a genuine share-gain/mix signal with NO disclosed dollar or volume base, so it cannot be converted to revenue without inventing a number. Net: a small, low-tenths topline lift with real but unquantifiable share-gain optionality behind it.

Bottom line: Flowing the ~$163M Connected Care growth at the 14.86% corporate adjusted net margin yields ~$24M incremental adjusted net income = +0.74% on the ~$3,245.6M adjusted earnings base. Sizing is done against the ADJUSTED base, not GAAP — off the depressed $1,678M GAAP NI the same $24M would print ~1.4%, an artifact of the distorted denominator. No AI cost-savings or productivity dollars were quantified, so there is no separable bottom-line efficiency story to add.

Consensus is dominated by BDX's portfolio separation, not AI: forward FY26 revenue $19,203M is DOWN ~12% vs the current $21,839M (Biosciences/Diagnostics separation), while adj EPS rises $11.30→$12.58 (+11.3%) on the reshaped, buyback-levered RemainCo. The AI-attributable lift that can actually be computed is +0.75% revenue / +0.74% EPS — roughly one-fifteenth of the consensus EPS move and well inside the Connected Care growth already embedded in estimates. AI is not a separable above-consensus driver here; it is a supporting mix/share-gain narrative inside numbers moved primarily by the separation and capital returns.

MODEL CONSENSUS (impact)

partial

Agree on adopter side, single sizeable claim, inline/priced-in. Key reconciliation: matched flow-through margin to the adjusted denominator, making rev% and EPS% near-equal.

Conflicts reconciled
FieldOpus 4.8GPT-5.5
Rev uplift %0.740.7564
EPS uplift %0.740.3906
Priced inhighhigh
vs analystsinlineinline
Confidence35
Top lineOnly one claim is sizeable on the disclosed inputs: the AI-driven Connected Care segment (~$4.9B, 22.4% of revenue) grew 3.3% in Q2, led by AI-driven APM +12%. Taken at face value that is ~$162M of incremental annual revenue = +0.74% on the $21,839M base. Everything else — Pyxis Pro's 85%/75% competitive-conversion wins, double-digit/10% pharmacy automation growth, and the Pyxis Pro price premium — is a genuine share-gain or mix signal but has NO disclosed dollar/volume base in the inputs, so it cannot be converted to revenue without inventing a number. Net: a small, low-single-digit-tenths topline lift, with real but unquantifiable share-gain optionality behind it.The only hard computable next-FY AI-linked uplift is Connected Care growth: $5.0B * 3.3% = $165.0M, equal to 0.7564% of BDX's $21.839B revenue base. The larger $5.0B figure is an addressed portfolio scale, not incremental AI revenue.
Bottom lineFlowing the ~$162M Connected Care growth at the 14.86% corporate adjusted net margin yields ~$24M incremental adjusted net income = +0.74% on the ~$3,245.6M adjusted earnings base (EPS$). I deliberately size against the ADJUSTED base, not GAAP — off the depressed $1,678M GAAP NI the same $24M would print ~1.4%, an artifact of the distorted denominator, not a real doubling of impact. No AI cost-savings or productivity dollars were quantified by management, so there is no separable bottom-line efficiency story to add.At the current 7.6835% net margin, the $165.0M revenue proxy contributes about $12.678M of net income. Against FY2025 consensus adjusted net income of $3.245563B, that is a 0.3906% EPS uplift.
ReasoningConsensus is dominated by BDX's portfolio separation, not AI: forward FY26 revenue $19,203M is DOWN 12.1% vs the current $21,839M (Biosciences/Diagnostics being separated), while adj EPS rises $11.30→$12.58 (+11.3%) on the reshaped, buyback-levered RemainCo. The AI-attributable lift I can actually compute is +0.74% revenue / +0.74% EPS — roughly one-fifteenth of the consensus EPS move and well inside the Connected Care growth already embedded in estimates. AI is not a separable above-consensus driver here; it is a supporting mix/share-gain narrative inside numbers that move for structural reasons. Nothing in the math points clearly above consensus, so priced_in is high.Consensus revenue falls from $21.858B for FY2025 to $19.203B for FY2026, mainly reflecting portfolio changes, then grows to $19.670B in FY2027, a $466.6M or 2.43% FY2027 increase. The hard AI-linked $165.0M revenue proxy is only 0.7564% of the current revenue base and sits well within normal segment growth assumptions. Consensus adjusted EPS rises from $11.30001 in FY2025 to $12.57897 in FY2026, up 11.32%, far above the computable 0.3906% EPS contribution, so the quantified AI impact does not point clearly above consensus.

Rows highlighted where the two models disagreed.

QUANTIFICATIONS
Connected Care business scale with AI-driven APM and connected medication management: nearly $5 billion (Q1 FY2026 call, current portfolio, topline)
“From our nearly $5 billion Connected Care business, with AI-driven advanced patient monitoring and connected medication management, to advanced pharmacy robotics, to leading platforms for biologic drug delivery at home, urinary incontinence, vascular disease, and tissue regeneration.”
Pyxis Pro competitive conversions: 85% of initial orders (Q1 FY2026, topline)
“The Pyxis Pro launch is off to a good start, with 85% of initial orders coming from competitive conversions.”
Pharmacy automation growth: double-digit growth (Q1 FY2026, topline)
“MMS growth was led by pharmacy automation with double-digit growth in our LoRa platform.”
Pharmacy automation growth: 10% in the quarter (Q1 FY2026, topline)
“Pharmacy automation is actually one of our largest percent businesses of CapEx, and it grew double digits, 10% in the quarter.”
Pyxis Pro pricing: premium to the base Pyxis (Q1 FY2026, both)
“Pyxis Pro launched at a premium to the base Pyxis.”
Pyxis Pro competitive conversions: 75% of wins (first half of FY2026, topline)
“Our early customer response has been strong. The launch is translating into competitive traction actually in the first half of the year now. 75% of our wins are competitive conversions which is reinforcing our view that this is really a meaningful share gain platform over time.”
APM growth: 12% (Q2 FY2026, topline)
“Connected Care grew 3.3%, led by Advanced Patient Monitoring which grew 12% on strength in the U.S. consumables.”
PAST (realized)
CURRENT (now)
FORWARD (guidance)
TRACK RECORD — PROMISE vs DELIVERY

80/100 track record   delivers  6 calls reviewed

BD made a small number of milestone-plus-timeframe AI-adjacent commitments (the Incada AI-enabled platform, the FACSDiscover A8 launch, and intelligent process improvements), and the judgeable ones were delivered on schedule; however none carried hard revenue/adoption numbers and the AI substance of some items is debatable, so the track record is positive but thinly evidenced.

Launch the first BD FACSDiscover Analyzer A8 (AI/imaging-enabled) in the second half of FY2025 — promised Q1 FY2025
delivered Q3 FY2025 confirmed a successful launch that exceeded sales targets, ahead of plan.
BD Incada enterprise AI-enabled platform to follow Pyxis Pro 'this quarter' — promised Q3 FY2025
delivered Q4 FY2025 said BD Incada AI-enabled platform had recently launched alongside Pyxis Pro; no quantified revenue/adoption target was attached.
Use BD Excellence in R&D to reduce development times by six to twelve months across several programs — promised Q1 FY2026
delivered Q2 FY2026 reported five programs reduced time-to-launch by over 10 months on average — directionally met, though this is intelligent-process improvement rather than an AI product.
PRICED-IN (REFINED)
MEDIUM

Est. revisions rising  ·  Fwd P/E 12.8  ·  EV/Sales 3.2x

AI claim maps to Life Sciences, Medical, Interventional

Estimate signals lean rising: recent price-target averages are moving up and buy counts have edged higher versus early 2026, even though EPS growth is only modest and revenue estimates are mixed. Rising estimates make AI upside more priced-in, but the forward P/E of 12.8 is not stretched for a mature medical instruments company while EV/Sales around 3.2 is moderate. AI-related productivity or revenue upside would most plausibly flow through Life Sciences, Medical, and Interventional, so the priced-in verdict is medium rather than high.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
2Q1 FY20252Q2 FY20258Q3 FY20257Q4 FY20257Q1 FY20265Q2 FY2026

AI enthusiasm across 6 calls — trend ↗ rising

AI moved from absent to a concrete Connected Care platform story, though Q2 FY2026 emphasized execution more than AI specifics.

RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY

7/10 qualitative impact   material  medium-term · mixed evidence

Where AI matters: Connected Care medication management, patient monitoring, pharmacy automation

AI is embedded in Pyxis Pro, BD Incada, advanced patient monitoring, and pharmacy automation, with tangible share-gain signals such as 75%-85% competitive-conversion wins and a premium Pyxis Pro launch. The disclosed dollars still point to a sub-1% near-term revenue/EPS lift, so this is material for an important business line rather than transformational for BDX overall.

Caveats: AI contribution is difficult to separate from broader Connected Care and automation growth; Hospital capex cycles and implementation friction could slow adoption; Competitors can add similar AI-enabled workflow features and compress differentiation; Regulatory, cybersecurity, and clinical-validation requirements may limit speed of rollout

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 1/10

AI does not automate away BD's core regulated devices, consumables, installed systems, or hospital workflow infrastructure; it mainly improves product differentiation and labor-saving value propositions. The main threat is competitive parity in AI features, not structural cannibalization of BD's revenue model.

OPTIONS / MARKET STRUCTURE

option liquidity: good

ATM IV
—
TYPICAL BID-ASK
—
OPEN INTEREST
—

proxy inputs — dollar-ADV $414M · beta 0.285 · px $144.43

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 2/10 hedged.
INSIDERS selling 10 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 132 new / 222 closed positions; 710 increased / 523 reduced; institutional ownership -15.12pp; -97 net 13F holders
MGMT LANGUAGE 2/10 hedged AI is essentially absent; automation appears only as a product line, with limited ownership beyond growth reporting.
commit “We also delivered mid- to high single-digit growth in oncology, peripheral arterial disease and Rowa pharmacy automation.”
hedge “While we're still in the early innings of applying BD Excellence to R&D, we're already seeing momentum.”
VERBATIM AI QUOTES
“The new Pyxis Pro is the first AI-enabled Pyxis, and it's the first future cloud-enabled Pyxis.”
— Thomas Polen, Q2 FY2026
“Our early customer response has been strong. The launch is translating into competitive traction actually in the first half of the year now. 75% of our wins are competitive conversions which is reinforcing our view that this is really a meaningful share gain platform over time.”
— Thomas Polen, Q2 FY2026
“What we're doing with that platform? So it enhances capacity, it enhances security and durability but it also has our new AI platform, BD Incada.”
— Thomas Polen, Q2 FY2026
“And under Bilal's leadership, he's really brought in a new team of AI specialists, data specialists who are building out Incada as our solution that all of our devices, whether or not it's Alaris or Pyxis or APM or other software platforms will all feed into this AI model that will help customers improve that end-to-end medication management workflow, improve inventory visibility.”
— Thomas Polen, Q2 FY2026
“And ultimately, that's our platform that we view connecting in our patient monitoring and the drug delivery side to take things to a next level of breakthrough innovation.”
— Thomas Polen, Q2 FY2026
“The trends around automation and labor shortages certainly are not changing anywhere, particularly Europe, right? When you go into hospitals, labor shortages are the #1 topic we hear time and time again, and pharmacy automation is a fantastic solution.”
— Thomas Polen, Q2 FY2026
“They don't have pharmacists counting pills and putting them in amber vials in their warehouses, right? They're using, in many cases, our automation to do that, and then they're shipping those to you, those online retailers.”
— Thomas Polen, Q2 FY2026
“That's allowing us to, again, have more scaled facilities where we can also invest in informatics, AI, BD Excellence capabilities that create a flywheel effect.”
— Thomas Polen, Q2 FY2026
“These include one, the rise of smart connected devices, robotics, AI, and informatics that transform the cost and quality of care;”
— Thomas E. Polen, Q1 FY2026
“From our nearly $5 billion Connected Care business, with AI-driven advanced patient monitoring and connected medication management, to advanced pharmacy robotics, to leading platforms for biologic drug delivery at home, urinary incontinence, vascular disease, and tissue regeneration.”
— Thomas E. Polen, Q1 FY2026
“New Becton, Dickinson and Company is positioned to lead in advancing the future of care.”
— Thomas E. Polen, Q1 FY2026
“The Pyxis Pro launch is off to a good start, with 85% of initial orders coming from competitive conversions.”
— Thomas E. Polen, Q1 FY2026
“MMS growth was led by pharmacy automation with double-digit growth in our LoRa platform.”
— Vitor Roach, Q1 FY2026
“Pharmacy automation is actually one of our largest percent businesses of CapEx, and it grew double digits, 10% in the quarter.”
— Thomas E. Polen, Q1 FY2026
“Again, that's a big labor savings play, and that's a big part of our CapEx spending as well as helping where there are shortages of pharmacists or other clinicians.”
— Thomas E. Polen, Q1 FY2026
“Pyxis Pro launched at a premium to the base Pyxis.”
— Thomas E. Polen, Q1 FY2026
“That it's delivering greater economic value to our customers, right? Those areas, for example, it's meaningful helping with nursing workflow by reducing drug shortages on the floor.”
— Thomas E. Polen, Q1 FY2026
“Or in the case of pharmacy automation, it's reducing labor costs associated with preparing medications and pills.”
— Thomas E. Polen, Q1 FY2026
ANALYST QUESTIONS ON AI
Q (Q2 FY2026, David Roman): Vitor, congratulations on the permanent role here as CFO, I look forward to working with you. Maybe just dive in a little bit deeper on MMS here. Clearly, a ton of focus on the Alaris business. But maybe you could help just frame for us some of the different other pieces in that line item. For example, what are the opportunities on the pump disposable side, especially given the disruption in a competitor? I believe your pump set share, especially sets outside the pump is lower than your pump capital share. You talked a little bit about Rowa and Parata. But maybe help us just break down a little bit further. Any detail you're willing to provide on sizing the businesses in there and how you're thinking about the growth trajectory, especially in light of the previously disclosed comments around the well-known Alaris headwinds?
A: "The new Pyxis Pro is the first AI-enabled Pyxis, and it's the first future cloud-enabled Pyxis." "75% of our wins are competitive conversions" and "it also has our new AI platform, BD Incada."
Q (Q1 FY2026, Joanne Wuensch): The first one has to do more macro, if you are seeing anything in the quarter on things like nursing shortages, weather impacts, or anything on the ACA?
A: "Pharmacy automation is actually one of our largest percent businesses of CapEx, and it grew double digits, 10% in the quarter." "Again, that's a big labor savings play, and that's a big part of our CapEx spending as well as helping where there are shortages of pharmacists or other clinicians."
Q (Q1 FY2026, Josh Jennings): Wanted to just get help thinking about the pricing environment hospitals, demands for concessions versus whether that's stepped up and just with all the innovation that's on tap for from Becton, Dickinson and Company, you know, can that help drive price premiums and pricing be a tailwind in fiscal 2026 and into the out years and help with organic revenue growth and gross margin expansion.
A: "Pyxis Pro launched at a premium to the base Pyxis." "Or in the case of pharmacy automation, it's reducing labor costs associated with preparing medications and pills."